Gene therapy treatment developed at the CNPRC shows benefits to brain cells for Alzheimer’s patients
Reporting on the first-of-its-kind human clinical trials designed to test the potential benefits of nerve growth factor gene therapy for Alzheimer’s patients, Mark Tuszynski, MD, PhD, CNPRC affiliate scientist, has found that an experimental gene therapy he developed at the California National Primate Research Center (CNPRC) at UC Davis reduces the rate at which nerve cells in the brains of Alzheimer’s patients degenerate and die (Tuszynski, M. H., et al. (2015).
